Clinical Validation of a Novel Software Tool to Guide the Intravenous-to-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases

被引：0
|
作者：
Hoffert, Yannick [1 ]
Wang, Zhigang [1 ]
Fumery, Mathurin [2 ,3 ]
Nachury, Maria [4 ]
Bazoge, Maeva [5 ]
Buisson, Anthony [5 ]
Dreesen, Erwin [1 ]
机构：
[1] Katholieke Univ Leuven, Leuven, Vlaams Brabant, Belgium
[2] Picardie Jules Verne Univ, CHU Amiens, Amiens, Picardie, France
[3] Picardie Jules Verne Univ, Peritox, Amiens, Picardie, France
[4] Lille Univ & Hosp, Lille, Nord Pas De Cal, France
[5] Univ Clermont Auvergne, CHU Clemront Ferrand, Clermont Ferrand, Auvergne, France
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001034524.01104.8d
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1289
引用
收藏
页码：S921 / S922
页数：2
相关论文
共 50 条
  • [31] Switching from intravenous to subcutaneous infliximab and vedolizumab in patients with inflammatory bowel disease: impact on trough levels, day hospital visits, and medical expenses
    Harno-Tasihin, Jenniina
    Siregar, Laura
    Paajanen, Mikko
    Arkkila, Perttu
    Punkkinen, Jari
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2024, 59 (03) : 280 - 287
  • [32] Switching from Intravenous to Subcutaneous Biological Therapy for Inflammatory Bowel Disease Patients Remains a Challenge
    Richter, Vered
    Cohen, Daniel L.
    Kriger-Sharabi, Ofra
    Zelnik Yovel, Dana
    Kochen, Nadav
    Broide, Efrat
    Shirin, Haim
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (05)
  • [33] Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission
    Guerrero Puente, Lourdes
    Iglesias Flores, Eva
    Manuel Benitez, Jose
    Medina Medina, Rosario
    Salgueiro Rodriguez, Isabel
    Aguilar Melero, Patricia
    Cardenas Aranzana, Manuel Jesus
    Gonzalez Fernandez, Rafael
    Manzanares Martin, Barbara
    Garcia-Sanchez, Valle
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2017, 40 (09): : 595 - 604
  • [34] Switching from intravenous to subcutaneous infliximab maintenance therapy in inflammatory bowel disease: Post hoc longitudinal analysis of a randomized trial
    Schreiber, Stefan
    D'Haens, Geert
    Cummings, Fraser
    Irving, Peter M.
    Ye, Byong Duk
    Ben-Horin, Shomron
    Kim, Dong-Hyeon
    Jeong, Ae Lee
    Reinisch, Walter
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (07) : 1204 - 1212
  • [35] Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases
    Volkers, Adriaan
    Straatmijer, Tessa
    Duijvestein, Marjolijn
    Sales, Amber
    Levran, Amit
    van Schaik, Fiona
    Maljaars, Jeroen
    Gecse, Krisztina
    Ponsioen, Cyriel
    Grootjans, Joep
    Hanzel, Jurij
    Tack, Greetje
    Jansen, Jeroen
    Hoentjen, Frank
    de Boer, Nanne
    van der Marel, Sander
    Dijkstra, Gerard
    Oldenburg, Bas
    Lowenberg, Mark
    van der Meulen, Andrea
    D'Haens, Geert
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (06) : 1044 - 1054
  • [36] Switching From Intravenous to Subcutaneous Infliximab is Safe and Feasible in Patients With Inflammatory Bowel Disease Suffering From Obesity: A Post Hoc Analysis of the REMSWITCH Study
    Buisson, Anthony
    Nachury, Maria
    Pereira, Bruno
    Fumery, Mathurin
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2024, 22 (05) : 1127 - 1129
  • [37] One-Year Clinical Outcomes of Subcutaneous Infliximab Maintenance Therapy Compared With Intravenous Infliximab Maintenance Therapy in Patients With Inflammatory Bowel Disease: A Prospective Cohort Study
    Hong, Sung Noh
    Song, Joo Hye
    Kim, Sung Jin
    Park, Yoon Ha
    Choi, Chang Wan
    Kim, Ji Eun
    Kim, Eun Ran
    Chang, Dong Kyung
    Kim, Young-Ho
    INFLAMMATORY BOWEL DISEASES, 2024, 30 (04) : 517 - 528
  • [38] Usefulness of subcutaneous Infliximab in patients with Inflammatory Bowel Disease in clinical practice: are increased levels associated with clinical benefit?
    Molina, I. Garcia De la Filia
    Gismero, F. Mesonero
    Cardona, J. Lopez
    Aldehuelo, R. Sanchez
    Gamboa, A. De la Serna
    Caro, T. Gramage
    Fernandez, C. Fernandez
    Garbine, R. A.
    Agustin, A. M.
    Roman, A. Lopez San
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1625 - I1627
  • [39] Fecal Calprotectin Decreases Following Transition to Subcutaneous CT-P13 in Patients With Inflammatory Bowel Diseases on Escalated Intravenous Infliximab Maintenance Therapy
    Wang, Zhigang
    Ferrante, Marc
    Vermeire, Severine
    Dreesen, Erwin
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S856 - S857
  • [40] Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study
    Buisson, A.
    Nachury, M.
    Reymond, M.
    Yzet, C.
    Wils, P.
    Payen, L.
    Manlay, L.
    Pereira, B.
    Fumery, M.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I393 - I394
12345